Gary W Pace bought $41k of CRDF
director at Cardiff Oncology, Inc.. 30,000 shares at an average of $1.37, traded Dec 19, 2023, filed Dec 19, 2023.
Score components
- +15RoleDirector
- +6Trade size$41k at market
- 0Relative to holdingsHoldings up 4.5%
- +8Price context38% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- +10Track recordMedian 6-month excess return +15% over 3 past buys
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +7.4%, 3m +258.1%, 6m +83.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-23-042045, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2023 | POpen-market purchase Common Stock | +30,000 | $1.37 | $41k | 697,761 | Dec 19, 2023 |
Related signals
Other insiders at Cardiff Oncology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 63Notable | Cardiff Oncology, Inc. | Mani Mohindru Chief Executive Officer | $50k 34,364 shares | +139% | |
| 71Notable | Cardiff Oncology, Inc. | Gary W Pace director | $1000k 687,285 shares | +51% | |
| 47Moderate | Cardiff Oncology, Inc. | Gary W Pace director | $37k 30,000 shares | +2% | |
| 64Notable | Cardiff Oncology, Inc. | Mani Mohindru Chief Executive Officer | $30k 24,703 shares | - | |
| 60Notable | CRDFbuy Cardiff Oncology, Inc. | Gary W Pace director | $711k 290,000 shares | +27% | |
| 46Moderate | Cardiff Oncology, Inc. | James E. Levine Chief Financial Officer | $37k 7,716 shares | +13% | |
| 46Moderate | Cardiff Oncology, Inc. | Renee P Tannenbaum director | $34k 10,000 shares | +100% | |
| 64Notable | Cardiff Oncology, Inc. | Gary W Pace director | $940k 361,615 shares | +52% | |
| 43Moderate | CRDFbuy Cardiff Oncology, Inc. | Gary W Pace director | $22k 22,950 shares | +4% | |
| 31Weak | CRDFbuy Cardiff Oncology, Inc. | James O Armitage director | $20k 13,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.